Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Liabilities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Total Liabilities for 3 consecutive years, with $21.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 8.59% to $21.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.0 million, a 8.59% decrease, with the full-year FY2025 number at $21.0 million, down 8.59% from a year prior.
  • Total Liabilities was $21.0 million for Q4 2025 at Artiva Biotherapeutics, up from $19.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $267.0 million in Q2 2024 to a low of $19.6 million in Q3 2025.
  • A 3-year average of $85.4 million and a median of $24.6 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 62.56% in 2024, then plummeted 92.38% in 2025.
  • Artiva Biotherapeutics' Total Liabilities stood at $50.7 million in 2023, then tumbled by 54.77% to $22.9 million in 2024, then dropped by 8.59% to $21.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Total Liabilities are $21.0 million (Q4 2025), $19.6 million (Q3 2025), and $20.3 million (Q2 2025).